Teresa Parli

975 total citations
20 papers, 393 citations indexed

About

Teresa Parli is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Teresa Parli has authored 20 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in Teresa Parli's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Teresa Parli is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Teresa Parli collaborates with scholars based in United States, Belgium and Netherlands. Teresa Parli's co-authors include Tomasz M. Beer, Bertrand Tombal, Andrew J. Armstrong, Celestia S. Higano, Ping Lin, Anthony M. Joshua, Fred Saad, Steve van Os, Brad Rosbrook and De Phung and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Teresa Parli

20 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Teresa Parli United States 9 279 125 97 96 73 20 393
Takuto Hara Japan 10 242 0.9× 72 0.6× 69 0.7× 105 1.1× 86 1.2× 76 354
Fred Saad Canada 5 248 0.9× 47 0.4× 84 0.9× 67 0.7× 74 1.0× 15 333
Marie Hjälm-Eriksson Sweden 8 367 1.3× 83 0.7× 111 1.1× 113 1.2× 87 1.2× 17 455
Jean François Berdah France 9 154 0.6× 62 0.5× 74 0.8× 101 1.1× 15 0.2× 25 246
Elie A. Benaim United States 12 309 1.1× 45 0.4× 64 0.7× 62 0.6× 79 1.1× 18 411
D. Phung United States 7 252 0.9× 122 1.0× 94 1.0× 93 1.0× 22 0.3× 25 328
Vinay Mathew Thomas United States 10 124 0.4× 41 0.3× 50 0.5× 76 0.8× 41 0.6× 52 312
Steve van Os United States 9 340 1.2× 122 1.0× 138 1.4× 199 2.1× 64 0.9× 15 612
Jean-François Caubet United States 6 255 0.9× 23 0.2× 44 0.5× 200 2.1× 114 1.6× 8 473
P. Stattin Sweden 7 257 0.9× 30 0.2× 160 1.6× 184 1.9× 186 2.5× 17 512

Countries citing papers authored by Teresa Parli

Since Specialization
Citations

This map shows the geographic impact of Teresa Parli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Parli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Parli more than expected).

Fields of papers citing papers by Teresa Parli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Parli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Parli. The network helps show where Teresa Parli may publish in the future.

Co-authorship network of co-authors of Teresa Parli

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Parli. A scholar is included among the top collaborators of Teresa Parli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Parli. Teresa Parli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hartsfield, Cynthia L., Deepak L. Bhatt, Harold Bays, et al.. (2024). Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia. Journal of clinical lipidology. 18(4). e552–e553. 1 indexed citations
2.
Bhatt, Deepak L., Harold Bays, Michael Miller, et al.. (2023). The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nature Medicine. 29(7). 1782–1792. 66 indexed citations
3.
Bhatt, Deepak L., Harold Bays, Michael Miller, et al.. (2023). PEGOZAFERMIN PROVIDES BENEFICIAL LIPID EFFECTS IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA REGARDLESS OF BACKGROUND LIPID MODIFYING THERAPY STATUS: AN ANALYSIS OF THE PHASE 2 ENTRIGUE STUDY. Journal of the American College of Cardiology. 81(8). 1765–1765. 2 indexed citations
4.
Armstrong, Andrew J., Ping Lin, Bertrand Tombal, et al.. (2020). Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. European Urology. 78(3). 347–357. 101 indexed citations
5.
Armstrong, Andrew J., Mohammed Al-Adhami, Ping Lin, et al.. (2019). Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. JAMA Oncology. 6(2). 217–217. 16 indexed citations
6.
Armstrong, Andrew J., Ping Lin, Celestia S. Higano, et al.. (2018). Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. European Urology Oncology. 2(6). 677–684. 25 indexed citations
7.
Rathkopf, Dana E., Tomasz M. Beer, Yohann Loriot, et al.. (2018). Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology. 4(5). 694–694. 34 indexed citations
8.
Devlin, Nancy, Michael Herdman, Marco Pavesi, et al.. (2017). Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health and Quality of Life Outcomes. 15(1). 130–130. 24 indexed citations
9.
Taplin, Mary-Ellen, Andrew J. Armstrong, Ping Lin, et al.. (2017). Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. The Journal of Urology. 198(6). 1324–1332. 6 indexed citations
10.
Morris, Michael J., Tomasz M. Beer, Yohann Loriot, et al.. (2016). Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.. Journal of Clinical Oncology. 34(2_suppl). 182–182. 1 indexed citations
11.
12.
Beer, Tomasz M., Andrew J. Armstrong, Cora N. Sternberg, et al.. (2015). Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.. Journal of Clinical Oncology. 33(15_suppl). 5036–5036. 10 indexed citations
13.
Graff, Julie N., G. Baciarello, Andrew J. Armstrong, et al.. (2015). Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Annals of Oncology. 27(2). 286–294. 86 indexed citations
14.
Moreau, Philippe, Paul G. Richardson, Andrzej Jakubowiak, et al.. (2012). A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 30(15_suppl). 8020–8020. 2 indexed citations
15.
Lam, Elaine T., S. Gail Eckhardt, Wells A. Messersmith, et al.. (2011). Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). C18–C18. 2 indexed citations
16.
17.
Lonial, Sagar, Andrzej Jakubowiak, Sundar Jagannath, et al.. (2011). A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 118(21). 303–303. 9 indexed citations
18.
Richardson, PG, Philippe Moreau, Andrzej Jakubowiak, et al.. (2011). Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.. Journal of Clinical Oncology. 29(15_suppl). 8014–8014. 1 indexed citations
19.
20.
Milla, Carlos, Frank J. Accurso, James F. Chmiel, et al.. (2009). A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with Pseudomonas aeruginosa.. A1190–A1190. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takuto Hara Breakdown of academic impact, for papers by Fred Saad Breakdown of academic impact, for papers by Marie Hjälm-Eriksson Breakdown of academic impact, for papers by Jean François Berdah Breakdown of academic impact, for papers by Elie A. Benaim Breakdown of academic impact, for papers by D. Phung Breakdown of academic impact, for papers by Vinay Mathew Thomas Breakdown of academic impact, for papers by Steve van Os Breakdown of academic impact, for papers by Jean-François Caubet Breakdown of academic impact, for papers by P. Stattin
Rankless by CCL
2026